Discover CME, tools, and guideline-focused education to improve your knowledge - and patient outcomes.
Retina Rumble: Debating Modern Treatment Options
Roger A. Goldberg, MD, MBA
Christina Y. Weng, MD, MBA, FASRS
Yasha S. Modi, MD
Incorporating Novel Muscarinic Agents for Schizophrenia Into Clinical Practice: Overcoming Clinical Inertia
May 28, 2026
Miami Beach, Florida
May 28, 2026 Miami Beach, Florida
07:00 AM - 08:00 AM ET
Redefining gMG Management: FcRn Antagonists and the New Era of Precision Neurology
September 30, 2026
11:45 AM - 12:45 PM ET
Orlando, Florida
Target Locked in gMG: Why T2T Matters
Christyn Edmundson, MD
Gil I. Wolfe MD, FAAN
The 2-Point Signal: Apply ≥2-Point Rule
The Future of HNSCC: Aligning Teams, Transforming Care
Ravindra Uppaluri, MD, PhD
Nancy Lee, MD, FASTRO
FcRn: Same Class, Different Paths—Spot Agent Differentiators
Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
Minimal By Design: Define MSE Endpoints
Treat. Target. Transform: Applying Treat-to-Target Principles in the Management of Generalized Myasthenia Gravis (gMG)
When to Begin FcRn: Initiation Criteria, Key Evidence
Turning Flares Into Function: Flag Uncontrolled Disease
The IgG Clock: Redose Using IgG Kinetics
Shared Goals, Shared Gains: Align With Patient Preferences
APRIL Uncovered: An Upstream Driver in IgAN
Dana Rizk, MD
Hong Zhang
The 4-Hit Hypothesis: Foundations of IgAN Pathogenesis
Richard Lafayette, MD, FACP
Mechanism-Based Targeting: Why APRIL Matters in IgAN
Suzuki Yusuke, MD, PhD
Inside the 4 Hits: Targeting APRIL to Change the Course of IgAN
IgAN SOC: Strengths and Limits
Emerging Evidence: IgAN Disease-Modifying Agents
Advancing Precision Diagnosis and Treatment Strategies in Acromegaly: A Q-Challenge Live Clinical Decision Experience
April 23, 2026
Las Vegas, Nevada
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.